NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55513-0954-01 | 55513-0954 | Panitumumab | Vectibix | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
70710-1034-01 | 70710-1034 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
70710-1033-01 | 70710-1033 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
70710-1031-01 | 70710-1031 | LENALIDOMIDE | LENALIDOMIDE | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 12, 2022 | In Use | |
55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov 18, 2010 | In Use | |
70710-1030-01 | 70710-1030 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
70121-1754-01 | 70121-1754 | Bevacizumab-maly | ALYMSYS | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 15, 2022 | In Use | |
70114-0340-01 | 70114-0340 | Toripalimab-tpzi | LOQTORZI | 240.0 mg/6mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Oct 27, 2023 | In Use | |
69097-0382-73 | 69097-0382 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
69097-0383-81 | 69097-0383 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
67457-0991-15 | 67457-0991 | Trastuzumab | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov 29, 2019 | Feb 28, 2027 | In Use |
43598-0515-01 | 43598-0515 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
55513-0326-01 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
00085-4347-01 | 00085-4347 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Aug 30, 2014 | Oct 18, 2020 | In Use | ||
55513-0224-01 | 55513-0224 | rituximab-arrx | Riabni | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
55513-0160-01 | 55513-0160 | Blinatumomab | Blincyto | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | Intravenous | Dec 18, 2014 | In Use | ||
55513-0141-01 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 28, 2019 | In Use | |
55513-0132-01 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 11, 2019 | In Use | |
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov 25, 2020 | In Use | |
43598-0514-01 | 43598-0514 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
66733-0958-23 | 66733-0958 | Cetuximab | Erbitux | 2.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 2, 2007 | In Use | |
83257-0004-12 | 83257-0004 | Trastuzumab-dkst | OGIVRI | Immunotherapy | Monoclonal Antibody | HER2 | Oct 1, 2023 | In Use | |||
55513-0079-01 | 55513-0079 | Talimogene Laherparepvec | Imlygic | 100000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov 2, 2015 | In Use | |
66733-0948-23 | 66733-0948 | Cetuximab | Erbitux | 2.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Feb 12, 2004 | In Use | |
66302-0014-01 | 66302-0014 | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | Intravenous | Mar 10, 2015 | In Use |
Found 11120 results — Export these results